Prothena (NASDAQ: PRTA) CSO converts 51,000 RSUs, disposes 51,000 shares at $8.56
Rhea-AI Filing Summary
Prothena Corp Public Ltd Co Chief Scientific Officer Wagner M. Zago exercised 51,000 restricted stock units into an equal number of ordinary shares on July 28, 2026. These units were part of an 85,000 RSU grant made on July 28, 2025. On the same date, he reported a transaction coded as a disposition to the issuer of 51,000 ordinary shares at $8.56 per share. Footnotes state that 34,000 RSUs from the 2025 grant remain subject to vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
51,000 shares exercised/converted
Exercise
3 txns
Insider
Zago Wagner M.
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F2, F1, F3 | 51,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares, par value $0.01 per share F1 | 51,000 | -- | -- |
| Disposition | Ordinary Shares, par value $0.01 per share | 51,000 | $8.56 | $437K |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Ordinary Shares, par value $0.01 per share — 34,000 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
- F2. These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 85,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
- F3. These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 85,000 RSUs reported in Table I (34,000 RSUs) are subject to vesting.
Key Figures
RSUs exercised: 51000.0000 units
Disposition share count: 51000.0000 shares
Disposition price: $8.5600 per share
+2 more
5 metrics
RSUs exercised
51000.0000 units
Restricted stock units converted into ordinary shares on July 28, 2026
Disposition share count
51000.0000 shares
Ordinary shares reported as a disposition to the issuer at $8.56 per share
Disposition price
$8.5600 per share
Price for 51,000 ordinary shares disposed to the issuer
Original RSU grant size
85,000 RSUs
RSUs granted to the reporting person on July 28, 2025
Unvested RSUs remaining
34,000 RSUs
Portion of the 85,000-unit grant that remains subject to vesting
Key Terms
Restricted Stock Units, Ordinary Shares, Disposition to issuer, vesting
4 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents the contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Disposition to issuer financial
"transaction_code_description": "Disposition to issuer""
vesting financial
"These RSUs reported in Table II are fully vested as of July 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Prothena (PRTA) report for Wagner M. Zago on July 28, 2026?
Prothena reported that Chief Scientific Officer Wagner M. Zago exercised 51,000 RSUs into ordinary shares on July 28, 2026 and, the same day, recorded a disposition to the issuer of 51,000 ordinary shares at $8.56 per share.
How many restricted stock units from the Prothena (PRTA) grant remain unvested for Wagner M. Zago?
From an original grant of 85,000 RSUs awarded on July 28, 2025, footnotes state that 34,000 RSUs remain subject to vesting. The 51,000 RSUs reported in this Form 4 were fully vested as of July 28, 2026.
Were Prothena (PRTA) Chief Scientific Officer Wagner M. Zago’s transactions under a Rule 10b5-1 plan?
The Rule 10b5-1 checkbox in the Form 4 is not marked, and the footnotes do not mention any Rule 10b5-1 trading plan, indicating these transactions were not reported as being made under such a pre-arranged plan.
What does each Prothena (PRTA) RSU reported for Wagner M. Zago represent?
A footnote explains that each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of Prothena upon vesting. Thus, 51,000 RSUs correspond to 51,000 ordinary shares when fully vested and settled.